| Biomarker ID | 866 |
| PMID | 22315056 |
| Year | 2012 |
| Biomarker | Testosterone |
| Biomarker Basis | Concentration Based (ng/ml) |
| Biomolecule | Protein |
| Source | Plasma |
| Subjects | Humans |
| Regulation | Downregulated in Gleason Score 8-9 |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Gleason Sum 5 Vs Gleason Sum 8-9 |
| Type of Biomarker | Prognostic |
| Cohort | Eighty-eight patients with localised, locally advanced, or metastatic PCa were recruited into study. Age-matched controls with benign prostate hyperplasia (BPH) (n = 110) with young healthy males with the very small chance of having PCa foci (n = 20) were included in this study. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.0495 |
| Method Used | AxSYM testosterone assay |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |